vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and WORKIVA INC (WK). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $247.3M, roughly 1.1× WORKIVA INC). WORKIVA INC runs the higher net margin — 7.7% vs -45.7%, a 53.4% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 19.9%). WORKIVA INC produced more free cash flow last quarter ($25.7M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 18.0%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Workiva, Inc. is a global software-as-a-service (SaaS) company. It provides a cloud-based connected and reporting compliance platform that enables the use of connected data and automation of reporting across finance, accounting, risk, and compliance.
GH vs WK — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $247.3M |
| Net Profit | $-128.5M | $19.0M |
| Gross Margin | 64.6% | 80.4% |
| Operating Margin | -43.0% | 25.8% |
| Net Margin | -45.7% | 7.7% |
| Revenue YoY | 39.4% | 19.9% |
| Net Profit YoY | -15.8% | — |
| EPS (diluted) | $-1.01 | $0.33 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $247.3M | ||
| Q4 25 | $281.3M | $238.9M | ||
| Q3 25 | $265.2M | $224.2M | ||
| Q2 25 | $232.1M | $215.2M | ||
| Q1 25 | $203.5M | $206.3M | ||
| Q4 24 | $201.8M | $199.9M | ||
| Q3 24 | $191.5M | $185.6M | ||
| Q2 24 | $177.2M | $177.5M |
| Q1 26 | — | $19.0M | ||
| Q4 25 | $-128.5M | $11.8M | ||
| Q3 25 | $-92.7M | $2.8M | ||
| Q2 25 | $-99.9M | $-19.4M | ||
| Q1 25 | $-95.2M | $-21.4M | ||
| Q4 24 | $-111.0M | $-8.8M | ||
| Q3 24 | $-107.8M | $-17.0M | ||
| Q2 24 | $-102.6M | $-17.5M |
| Q1 26 | — | 80.4% | ||
| Q4 25 | 64.6% | 80.7% | ||
| Q3 25 | 64.7% | 79.3% | ||
| Q2 25 | 65.0% | 77.0% | ||
| Q1 25 | 63.3% | 76.6% | ||
| Q4 24 | 61.6% | 77.1% | ||
| Q3 24 | 61.1% | 76.5% | ||
| Q2 24 | 59.1% | 76.8% |
| Q1 26 | — | 25.8% | ||
| Q4 25 | -43.0% | 3.3% | ||
| Q3 25 | -37.3% | -1.5% | ||
| Q2 25 | -45.9% | -10.3% | ||
| Q1 25 | -54.6% | -12.0% | ||
| Q4 24 | -62.4% | -6.7% | ||
| Q3 24 | -61.3% | -11.7% | ||
| Q2 24 | -56.8% | -13.0% |
| Q1 26 | — | 7.7% | ||
| Q4 25 | -45.7% | 4.9% | ||
| Q3 25 | -35.0% | 1.2% | ||
| Q2 25 | -43.0% | -9.0% | ||
| Q1 25 | -46.8% | -10.4% | ||
| Q4 24 | -55.0% | -4.4% | ||
| Q3 24 | -56.3% | -9.2% | ||
| Q2 24 | -57.9% | -9.9% |
| Q1 26 | — | $0.33 | ||
| Q4 25 | $-1.01 | $0.21 | ||
| Q3 25 | $-0.74 | $0.05 | ||
| Q2 25 | $-0.80 | $-0.35 | ||
| Q1 25 | $-0.77 | $-0.38 | ||
| Q4 24 | $-0.90 | $-0.15 | ||
| Q3 24 | $-0.88 | $-0.31 | ||
| Q2 24 | $-0.84 | $-0.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $334.3M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | — |
| Total Assets | $2.0B | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $334.3M | ||
| Q4 25 | $378.2M | $338.8M | ||
| Q3 25 | $580.0M | $315.9M | ||
| Q2 25 | $629.1M | $284.3M | ||
| Q1 25 | $698.6M | $242.0M | ||
| Q4 24 | $525.5M | $301.8M | ||
| Q3 24 | $585.0M | $248.2M | ||
| Q2 24 | $933.7M | $267.9M |
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $-99.3M | $-5.4M | ||
| Q3 25 | $-354.5M | $-36.9M | ||
| Q2 25 | $-305.5M | $-66.5M | ||
| Q1 25 | $-250.8M | $-75.7M | ||
| Q4 24 | $-139.6M | $-41.7M | ||
| Q3 24 | $-60.1M | $-50.8M | ||
| Q2 24 | $-1.6M | $-77.7M |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $2.0B | $1.5B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.3B | $1.3B | ||
| Q1 25 | $1.3B | $1.3B | ||
| Q4 24 | $1.5B | $1.4B | ||
| Q3 24 | $1.5B | $1.3B | ||
| Q2 24 | $1.6B | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | — |
| Free Cash FlowOCF − Capex | $-54.2M | $25.7M |
| FCF MarginFCF / Revenue | -19.3% | 10.4% |
| Capex IntensityCapex / Revenue | 9.9% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $171.9M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-26.4M | $51.0M | ||
| Q3 25 | $-35.4M | $46.2M | ||
| Q2 25 | $-60.3M | $50.3M | ||
| Q1 25 | $-62.7M | $-7.4M | ||
| Q4 24 | $-64.5M | $44.0M | ||
| Q3 24 | $-51.1M | $18.9M | ||
| Q2 24 | $-94.0M | $-14.0K |
| Q1 26 | — | $25.7M | ||
| Q4 25 | $-54.2M | $50.7M | ||
| Q3 25 | $-45.8M | $46.1M | ||
| Q2 25 | $-65.9M | $49.3M | ||
| Q1 25 | $-67.1M | $-8.1M | ||
| Q4 24 | $-83.4M | $43.2M | ||
| Q3 24 | $-55.3M | $18.7M | ||
| Q2 24 | $-99.1M | $-122.0K |
| Q1 26 | — | 10.4% | ||
| Q4 25 | -19.3% | 21.2% | ||
| Q3 25 | -17.3% | 20.5% | ||
| Q2 25 | -28.4% | 22.9% | ||
| Q1 25 | -33.0% | -3.9% | ||
| Q4 24 | -41.3% | 21.6% | ||
| Q3 24 | -28.9% | 10.1% | ||
| Q2 24 | -55.9% | -0.1% |
| Q1 26 | — | — | ||
| Q4 25 | 9.9% | 0.1% | ||
| Q3 25 | 3.9% | 0.0% | ||
| Q2 25 | 2.4% | 0.5% | ||
| Q1 25 | 2.2% | 0.4% | ||
| Q4 24 | 9.4% | 0.4% | ||
| Q3 24 | 2.2% | 0.1% | ||
| Q2 24 | 2.9% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | 4.31× | ||
| Q3 25 | — | 16.57× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
WK
| Subscription and support | $225.4M | 91% |
| Other | $22.0M | 9% |
